befotertinib   Click here for help

GtoPdb Ligand ID: 12951

Synonyms: compound 4 [WO2019218987A1] [2] | D-0316 | D0316 | Surmana®
Approved drug
befotertinib is an approved drug (China NMPA (2023))
Compound class: Synthetic organic
Comment: Befotertinib (D-0316) is an third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that was developed as a treatment for non-small cell lung cancer (NSCLC) [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 13
Topological polar surface area 84.8
Molecular weight 567.61
XLogP 3.32
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)NC1=C(C=C(C(=C1)NC2=NC=CC(=N2)C3=CN(CC(F)(F)F)C4=C3C=CC=C4)OC)N(C)CCN(C)C
Isomeric SMILES CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=CC(=N2)C3=CN(C4=CC=CC=C43)CC(F)(F)F)OC
InChI InChI=1S/C29H32F3N7O2/c1-6-27(40)34-22-15-23(26(41-5)16-25(22)38(4)14-13-37(2)3)36-28-33-12-11-21(35-28)20-17-39(18-29(30,31)32)24-10-8-7-9-19(20)24/h6-12,15-17H,1,13-14,18H2,2-5H3,(H,34,40)(H,33,35,36)
InChI Key USOCZVZOXKTJTI-UHFFFAOYSA-N
Bioactivity Comments
Befotertinib inhibits proliferation of NSCLC cells with IC50 values of 543 nM (WT EGFR) and 15.7 (EGFR with double mutant L858R/T790M) [3].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
epidermal growth factor receptor Hs Inhibitor Inhibition - - - 3
[3]